Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Puma Biotechnology to post earnings of $0.11 per share and revenue of $52.00 million for the quarter.

Puma Biotechnology Price Performance

Shares of PBYI opened at $3.22 on Wednesday. Puma Biotechnology has a 1-year low of $2.22 and a 1-year high of $4.13. The stock has a market cap of $159.81 million, a PE ratio of 4.18 and a beta of 1.30. The firm has a 50-day simple moving average of $3.41 and a two-hundred day simple moving average of $3.19. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 22nd.

Insider Transactions at Puma Biotechnology

In other news, Director Jay M. Moyes sold 22,000 shares of the business’s stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $74,800.00. Following the completion of the sale, the director owned 53,322 shares in the company, valued at approximately $181,294.80. The trade was a 29.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alessandra Cesano sold 27,000 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $3.37, for a total transaction of $90,990.00. Following the sale, the director owned 41,850 shares of the company’s stock, valued at $141,034.50. This represents a 39.22% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 173,649 shares of company stock valued at $596,914. 23.30% of the stock is owned by corporate insiders.

Institutional Trading of Puma Biotechnology

Several institutional investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in Puma Biotechnology by 3.8% in the 1st quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 3,117 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Puma Biotechnology by 366.5% in the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 39,641 shares in the last quarter. Invesco Ltd. grew its stake in Puma Biotechnology by 88.9% in the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 17,707 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Puma Biotechnology in the 1st quarter valued at about $66,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.